Hikal is fundamentally a science-driven contract manufacturer - a B2B partner that global pharmaceutical, animal-health and crop-protection innovators hire to develop and produce complex chemical molecules they would rather not make themselves. Founded in 1988 by Jai Hiremath as a chemical business, the company grew by acquiring established plants from multinationals like Novartis and by signing decade-long supply deals that turned customers into co-investors, a pattern that still defines its expansion. The recurring approach is to lock in long-term relationships with a handful of large innovators, then build dedicated, regulator-approved capacity behind those commitments - so every new factory wing tends to arrive with a customer already attached.
Business segments
Three engines built on the same CDMO model, serving different end markets - a pharmaceutical platform that is the group’s anchor, a crop-protection business that is its original roots, and a younger animal-health franchise that was incubated from the other two.
1. Pharmaceuticals: the anchor engine, making complex drug ingredients for global innovators
The division runs two intertwined models - selling its own portfolio of niche generic APIs and acting as a long-term outsourced manufacturing arm for innovator pharma companies, with both streams flowing through the same US FDA-approved plants.
- Own APIs in hard-to-copy therapies - the company has 31 commercialised APIs and 74 active US Drug Master Files, concentrated in oncology, central nervous system, gastroenterology and anti-diabetic segments where regulatory barriers are higher. It is now filing 5-6 DMFs a year, roughly double its historical pace, to deepen that protective moat.
- CDMO work rides the China Plus One wave - global innovators are actively diversifying their supply chains toward India, and Hikal is capturing that shift with 12-15 early-stage projects under discussion and two new chemical entities in Phase III trials that could commercialise by 2026-27.
- Plants bought, not just built - the Panoli site was acquired from Novartis in 2000 and the Bangalore site from Wintac a year later, giving the company ready-made, regulator-approved infrastructure that remains core to its pharma operations today. The Panoli API facility recently received a ‘No Action Indicated’ classification from the US FDA, the cleanest possible audit outcome.
- Betting on high-potency and cancer-linked chemistries - a high-potency API laboratory and pilot plant are already operational, and a dedicated HPAPI manufacturing facility is targeted for FY28, positioning the company for antibody-drug conjugate supply chains that are expected to take 3-5 years to scale.
2. Crop Protection: the original business, now pivoting from commoditised supply to deeper partnerships
After more than 30 years making insecticides, fungicides and herbicides, the division is shifting away from simple product sales toward co-development and long-term contract manufacturing agreements that lock in better margins.
- Recovering from a China-led price war - the global crop-protection industry has been through a multi-year inventory correction and intense price competition from Chinese overcapacity, which squeezed the division’s traditional own-product business.
- CDMO is already the bigger half - contract manufacturing for innovator companies contributed 52% of the Pharmaceuticals division’s revenue in FY26, and the company is now onboarding deeper engagements that bundle R&D, co-development and multi-year supply commitments.
- Three plants, one new wing - manufacturing is spread across Mahad (the company’s first site, 549 m³ reactor volume), Taloja (commissioned in 1997 with an innovator partner, 593 m³) and Panoli (acquired from Novartis, 720 m³ for crop protection), with a new multipurpose facility at Panoli recently qualified.
- Chemistry that opens new doors - the division successfully commercialised a hazardous azidation-chemistry project and used hydrogen-isotope-exchange chemistry to enter the OLED materials market, demonstrating the kind of complex-synthesis capability that attracts innovator clients.
3. Animal Health: the growth bet, built on a decade-long deal with a single anchor customer
A dedicated CDMO platform making APIs for farm and companion-animal medicines, anchored by a 10-year multi-product contract where the customer co-invested in the factory - so the asset was born with demand attached.
- One contract, one factory, eight products - the 2021 deal with a leading global animal-health innovator included joint investment in a multipurpose plant at Panoli, commissioned in late FY24, and all eight products under that partnership have now been validated and are shipping commercially.
- The only GMP source for a dog dermatology drug - Hikal holds the sole US Veterinary Master File for an API treating inflammatory skin conditions in dogs, and is a leading manufacturer of a morphine-like painkiller used across dogs, cats and horses.
- Moving up the complexity ladder - the portfolio is deliberately shifting toward differentiated, harder-to-replicate molecules where competitive intensity is lower, with new development projects covering both novel chemical entities and niche existing drugs.
- An extension of existing know-how - the division draws on synthesis and impurity-profiling capabilities built in human pharma and crop protection, and management has noted that some chemicals used to kill crop pests are chemically similar to those used in tick treatments for animals.
Research and Technology
A single integrated R&D engine serves all three business divisions, turning customer briefs - sometimes just a CAS number - into factory-ready processes, which is what makes the CDMO promise credible.
- 358 people, one campus - the Pune R&T centre houses 15 synthetic labs, a high-potency lab, a kilo lab for scale-up, a process safety lab and a solid-state chemistry lab, staffed by over 250 postgraduates and 26 PhDs.
- Dangerous chemistry as a selling point - the team has run over 50 batches in a cryogenic reactor at -80°C handling pyrophoric reagents, and secured repeat orders for hazardous Click Chemistry projects, the kind of work most customers prefer to outsource.
- Filing patents and DMFs from the lab - the R&T group filed 8 US DMFs in FY25 and has submitted patent applications for three animal-health APIs developed in-house, building an intellectual-property layer on top of the manufacturing business.
Group structure and partners
The company is a single listed entity with two small subsidiaries, controlled by the founding Hiremath family through a recently restructured holding vehicle, with strategic minority stakes in renewable-energy projects that power its factories.
- Founder-led, family-controlled - Executive Chairman Jai Hiremath founded the business in 1988, and his son Sameer Hiremath serves as Vice Chairman and Managing Director; the board also includes members of the Kalyani family.
- Holding company restructured - in late 2025, promoter shares held through two investment firms were amalgamated into Castilia Life Sciences, which converted to an LLP in February 2026, leaving the combined promoter group holding at 34.83%.
- Captive green power - the company has taken minority stakes in three solar and wind special-purpose vehicles and signed long-term power purchase agreements across its manufacturing sites, locking in renewable electricity for its own consumption.
- Global offices in the markets that matter - beyond its Indian manufacturing base, Hikal maintains commercial offices in the US, Europe and Japan, with the Tokyo office operating since 2009 to serve what is now a large part of the total business.